Professor Agnes Noel is testing combinations of drugs that stop two different proteins from working to see if they offer potential as a future treatment for patients with triple negative breast cancer.

Professor Chris Lord is investigating how breast cancers with changes in BRCA genes can become resistant to a group of drugs called PARP inhibitors. He hopes to improve treatments for people with this type of breast cancer.

Professor Simak Ali and Dr Lesley-Ann Martin are investigating how proteins called CDKs play a part in cancer’s resistance to palbociclib – a drug used to treat oestrogen receptor positive (ER+) secondary breast cancer. He is exploring whether blocking a protein called CDK7 could be a new way to treat tumours that have become resistant to palbociclib.

Professor Jukka Westermarck is finding new ways to predict which existing drugs will be most effective for triple negative breast cancers. He is investigating how different combinations of altered proteins in cancer cells affect their response to a number of experimental drugs.

Professor Catrin Pritchard and her team has developed a new, more personalised type of tumour model to test drugs before they enter clinical trials. She is exploring whether this system can more accurately represent how drugs will work when given to patients.

Professor Chris Twelves and colleagues are testing in the lab whether intelligently timing a drug palbociclib and chemotherapy can make the combination more effective. If successful, this approach will be tested in clinical trials for breast cancer.